Brief: Alligator Bioscience, Aptevo Therapeutics Announce FDA Issues "May Proceed" Notification
Sept 19 (Reuters) - Alligator Bioscience AB ATORX.ST :
* ALLIGATOR BIOSCIENCE AND APTEVO THERAPEUTICS ANNOUNCE THAT
FDA
HAS ISSUED A “MAY PROCEED” NOTIFICATION FOR THE ALG.APV-527 IND
Source text for Eikon: ID:nMFNbkQzjS
Further company coverage: APVO.O
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Alligator Bioscience AB
See all newsSweden's Alligator Bioscience Q3 sales fall as R&D winds down
Brief: Alligator Bioscience Q3 EBIT SEK -19.3 Million
Brief: Alligator Bioscience Appoints Johan Gileus As CEO
Brief: Alligator Bioscience Announces Final Outcome In Rights Issue
Brief: Alligator Bioscience To Initially Receive SEK 58.8 Mln From Rights Issue